| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3979472 | Bulletin du Cancer | 2010 | 7 Pages |
Abstract
Biomarkers status may change between primary and metastatic sites in CRC, with potential implications for the identification of patients who are likely to respond to anti-EGFR treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A. Barbier, J. Domont, N. Magné, J.-L. Goldmard, C. Genestie, C. Hannoun, J.-C. Vaillant, A. Bellanger, D. Khayat, F. Capron, J.-P. Spano,